Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor. Nishihara R, Shimomura A, Shimizu C. J Clin Oncol 2022;40:4280-4281.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nishihara R, Shimomura A, Shimizu C. Oral Selective Estrogen Receptor Degrader After Endocrine Therapy With a Cyclin-Dependent Kinase 4/6 Inhibitor. J Clin Oncol 2022;40:4280-4281.
PMID: 36067450